David Moffat, Macrophage Pharma

"Always challenge dogma & assumption...we were told that we'd never make drugs with kinases, but 30 years later there are over 50 kinase inhibitors on the market, they account for probably 30% of R&D spend and generate revenues of over $50bn." David Moffat is the Chief Technology Officer at Macrophage Pharma, a company harnessing macrophages to treat disease in areas of real need. David joined us to talk about his career, challenging dogma and why not making a decision is a big mistake in Biotech. Enjoy! (You can find the article that David discusses in his interview here: https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01445)